Novartis to Acquire Tourmaline Bio, Expanding ASCVD Pipeline
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
biopharma innovation
Advertisement
FDA Adds Modeyso (dordaviprone) to Oncology Guidelines for H3 K27M-Mutant Diffuse Glioma
September 9, 2025 – In a significant advancement for neuro-oncology, Modeyso (dordaviprone) has been included in the National Oncology...
UK Approves Once-Monthly Octreotide Injection for Acromegaly Care
Lund, Sweden — August 28, 2025 — The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval...
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...
Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations
Nanoscope Therapeutics, a biotechnology company advancing disease-agnostic optogenetic therapies for retinal degenerations, announced a major global regulatory milestone with...
Advertisements
Imbed Biosciences Gains FDA IDE for Silver-Gallium Wound Matrix Trial
Imbed Biosciences has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE)...
FDA Approves Updated 2025–2026 COVID-19 Vaccines from Pfizer, Moderna, and Novavax
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
FDA Ends Broad Emergency Authorization, Approves Updated COVID-19 Vaccines
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
AbbVie Acquires Gilgamesh Pharmaceuticals’ Bretisilocin, A Novel Psychedelic Therapy for Major Depressive Disorder
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation...
FDA Approval of PharmaTher’s Ketamine Product KETARx
PharmaTher Holdings Ltd. announced FDA approval of KETARx™, its ketamine product for anesthesia and sedation, marking a significant milestone...
Advertisement
